The poster, "Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Reduces Potentially Atherogenic Lipid, Lipoprotein, Apolipoprotein, and Inflammatory Parameters in High-Risk, Statin-Treated Patients With Persistent Elevated Triglycerides and High-Sensitivity C-reactive Protein: A Post hoc Subanalysis of the ANCHOR Study," reported that in statin-treated patients with TGs 200-499 mg/dL and hsCRP ≥2.0 mg/L, icosapent ethyl 4 g/day significantly reduced TGs and other potentially atherogenic and inflammatory parameters without increasing LDL-C vs. placebo. There was an 18%, statistically significant reduction of hsCRP as compared to placebo in this 12-week ANCHOR post-hoc analysis (p=0.02). Safety results were comparable to placebo, also consistent with overall ANCHOR study results.
The limitations of this analysis in statin-treated patients with hsCRP ≥2.0 mg/L and high TG at baseline include the modest sample size (n=126 and n=120, in the icosapent ethyl and placebo groups, respectively) and the post hoc nature of the analysis. hsCRP is a high-sensitivity quantification of C-reactive protein, an acute-phase protein released into the blood by the liver during inflammation, which has been associated with the presence of heart disease. As hsCRP is an acute-phase reactant and has high intra-individual variability, a single test for hsCRP, as was performed at each timepoint of the ANCHOR trial, may not accurately reflect an individual patient's basal or on-treatment hsCRP levels. Repeat measurement may be required to firmly establish an individual's basal hsCRP concentration, as well as to accurately understand treatment-induced changes in hsCRP. Moderate hsCRP levels (1-10 mg/L) have been associated with cardiovascular disease.
The ANCHOR study was not designed to determine effects on hsCRP or CV events. The ANCHOR trial was a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal Phase 3 study in patients with high TGs (≥200 mg/dL and < 500 mg/dL) who were also on statin therapy. 702 patients were enrolled in this trial. The primary endpoint in the trial was the percentage change in TG levels from baseline of Vascepa-treated subjects compared to placebo after 12 weeks of treatment. In
The clinical relevance of these data has not been determined. Amarin's REDUCE-IT trial is evaluating the potential benefit of icosapent ethyl on CV outcomes in statin-treated patients with high CV risk, including some patients with hsCRP ≥2.0 mg/L.
"We are excited to show the impact of Vascepa on these lipid and inflammatory biomarkers in patients with elevated hsCRP levels," expressed
The authors of this study were
Amarin's clinical development program for Vascepa includes a trial known as the REDUCE-IT cardiovascular outcomes study, an 8,175-patient study commenced in 2011. REDUCE-IT is the first multinational cardiovascular outcomes study evaluating the effect of prescription pure EPA therapy, or any triglyceride lowering therapy, as an add-on to statins in patients with high cardiovascular risk who, despite stable statin therapy, have elevated triglyceride levels (150-499 mg/dL). A large portion of the male and female patients enrolled in this outcomes study are anticipated to also be diagnosed with type 2 diabetes. As reported previously, Amarin expects to announce top-line results of this important study before the end of Q3 2018. The REDUCE-IT trial is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.
Additional information on clinical studies of Vascepa can be found at www.clinicaltrials.gov.
About VASCEPA® (icosapent ethyl) Capsules
Vascepa® (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex
FDA-Approved Indication and Usage
Important Safety Information for Vascepa
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
Vascepa has been approved for use by the
This press release contains forward-looking statements, including statements about the potential efficacy and therapeutic benefits of Vascepa, including statements about the unknown clinical relevance of the findings presented as well as statements concerning the REDUCE-IT cardiovascular outcomes study such as the anticipated inclusion
of certain patient populations, related timing and announcements with respect to final outcomes and the anticipated successful completion of the REDUCE-IT study. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with retrospective subset analyses, research on biomarkers thought to be relevant in the treatment of cardiovascular disease, research and development and clinical trial risk generally, including the risk that study results in modest sample sizes may not be predictive of future results in larger studies, that studied parameters may not have clinically meaningful effect and the risk that patents may not adequately protect Vascepa against competition. A further list
and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs,
Amarin Contact Information
Investor Relations and Corporate Communications
In U.S.: +1 (908) 719-1315
In U.S.: +1 (646) 378-2992
In U.S.: +1 (212) 583-2791
News Provided by Acquire Media